• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肝细胞癌中增强子RNA的综合表征揭示了三种免疫亚型及其对免疫治疗的意义。

Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy.

作者信息

Bu Xiaoyun, Liu Shuang, Wen Dongsheng, Kan Anna, Xu Yujie, Lin Xuanjia, Shi Ming

机构信息

Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

出版信息

Mol Ther Oncolytics. 2022 Jul 6;26:226-244. doi: 10.1016/j.omto.2022.07.001. eCollection 2022 Sep 15.

DOI:10.1016/j.omto.2022.07.001
PMID:35919459
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9310078/
Abstract

Hepatocellular carcinoma (HCC) is highly heterogeneous. Molecular subtyping for guiding immunotherapy is warranted. Previous studies have indicated that enhancer RNAs (eRNAs) are involved in tumor heterogeneity and immune infiltration. However, the eRNA landscape and its correlation with immune infiltration in HCC remain unknown. Here we first revealed the genome-wide eRNA landscape in two HCC cohorts. Then we divided individuals with HCC into three immune-related clusters (C1, C2, and C3) based on eRNA expression profiles. The prognosis, biological properties, immune infiltration, clinical features, genomic features, and drug response were analyzed. C1 was enriched in immune infiltration and potentially sensitive to immune checkpoint inhibitors (ICIs). C2 displayed features of immune depletion, high proliferation activity, malignant clinical features, and the worst prognosis. C2 may benefit from targeted therapy. C3 presented moderate immune infiltration, metabolism-related signatures, and the best prognosis. Transarterial chemoembolization (TACE) may be effective for C3. Finally, we constructed a 51-eRNA classifier for subtype prediction and validated its efficacy in The Cancer Genome Atlas (TCGA) cohort and Sun Yat-sen University Cancer Center (SYSUCC) cohort. Our results provide a novel method for immune classification of HCC, shed new light on tumor heterogeneity, and may aid in HCC immunotherapy.

摘要

肝细胞癌（HCC）具有高度异质性。有必要进行分子分型以指导免疫治疗。先前的研究表明，增强子RNA（eRNA）参与肿瘤异质性和免疫浸润。然而，HCC中eRNA的全貌及其与免疫浸润的相关性仍不清楚。在此，我们首先揭示了两个HCC队列中的全基因组eRNA全貌。然后，我们根据eRNA表达谱将HCC患者分为三个免疫相关簇（C1、C2和C3）。分析了其预后、生物学特性、免疫浸润、临床特征、基因组特征和药物反应。C1富含免疫浸润，可能对免疫检查点抑制剂（ICI）敏感。C2表现出免疫耗竭、高增殖活性、恶性临床特征和最差的预后。C2可能从靶向治疗中获益。C3呈现中度免疫浸润、代谢相关特征和最佳预后。经动脉化疗栓塞术（TACE）对C3可能有效。最后，我们构建了一个包含51个eRNA的分类器用于亚型预测，并在癌症基因组图谱（TCGA）队列和中山大学肿瘤防治中心（SYSUCC）队列中验证了其有效性。我们的结果为HCC的免疫分类提供了一种新方法，为肿瘤异质性提供了新的见解，并可能有助于HCC的免疫治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/5038b8b50e37/gr12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/8aa07f80cb91/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/49908e254262/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/346defd4ad67/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/b0f6bb176010/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/7d9042d795c5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/0282b63e1d8e/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/86da9128486d/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/408c568b4492/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/3c0f51d7f609/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/b415d26e793a/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/cacaca7fb2b3/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/7fcbbc2a44c8/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/5038b8b50e37/gr12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/8aa07f80cb91/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/49908e254262/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/346defd4ad67/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/b0f6bb176010/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/7d9042d795c5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/0282b63e1d8e/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/86da9128486d/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/408c568b4492/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/3c0f51d7f609/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/b415d26e793a/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/cacaca7fb2b3/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/7fcbbc2a44c8/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/392c/9310078/5038b8b50e37/gr12.jpg

相似文献

1
Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy.肝细胞癌中增强子RNA的综合表征揭示了三种免疫亚型及其对免疫治疗的意义。
Mol Ther Oncolytics. 2022 Jul 6;26:226-244. doi: 10.1016/j.omto.2022.07.001. eCollection 2022 Sep 15.
2
Comprehensive profiling of enhancer RNA in stage II/III colorectal cancer defines two prognostic subtypes with implications for immunotherapy.全面分析 II/III 期结直肠癌中的增强子 RNA，定义了两种具有免疫治疗意义的预后亚型。
Clin Transl Oncol. 2024 Apr;26(4):891-904. doi: 10.1007/s12094-023-03319-x. Epub 2023 Sep 12.
3
Comprehensive analysis of N6-methyladenosine-related lncRNAs reveals distinct hepatocellular carcinoma subtypes with immunotherapeutic implications.对N6-甲基腺嘌呤相关长链非编码RNA的综合分析揭示了具有免疫治疗意义的不同肝细胞癌亚型。
Am J Transl Res. 2022 Sep 15;14(9):6504-6520. eCollection 2022.
4
CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma.CD8+ T 细胞轨迹亚型解析肿瘤异质性并为肝细胞癌提供治疗建议。
Front Immunol. 2022 Jul 27;13:964190. doi: 10.3389/fimmu.2022.964190. eCollection 2022.
5
Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy.基于线粒体自噬的肝细胞癌亚型免疫特征及免疫治疗反应的研究
Front Immunol. 2022 Oct 11;13:966167. doi: 10.3389/fimmu.2022.966167. eCollection 2022.
6
Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma.肝细胞癌中用于预后的新型乳酸代谢特征和分子亚型的鉴定
Front Cell Dev Biol. 2022 Sep 2;10:960277. doi: 10.3389/fcell.2022.960277. eCollection 2022.
7
Identification and Validation of an Immune-Related eRNA Prognostic Signature for Hepatocellular Carcinoma.肝细胞癌免疫相关eRNA预后标志物的鉴定与验证
Front Genet. 2021 Jun 11;12:657051. doi: 10.3389/fgene.2021.657051. eCollection 2021.
8
Immune cell infiltration and immunotherapy in hepatocellular carcinoma.免疫细胞浸润与肝癌的免疫治疗。
Math Biosci Eng. 2022 May 16;19(7):7178-7200. doi: 10.3934/mbe.2022339.
9
Tumor biology, immune infiltration and liver function define seven hepatocellular carcinoma subtypes linked to distinct drivers, survival and drug response.肿瘤生物学、免疫浸润和肝功能定义了七种与不同驱动因素、生存和药物反应相关的肝细胞癌亚型。
Comput Biol Med. 2023 Dec;167:107593. doi: 10.1016/j.compbiomed.2023.107593. Epub 2023 Oct 18.
10
Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis.弥漫性胶质瘤的三种免疫相关亚型在免疫浸润、免疫检查点分子和预后方面存在差异。
Front Oncol. 2020 Dec 23;10:586019. doi: 10.3389/fonc.2020.586019. eCollection 2020.

引用本文的文献

1
Enhancer RNAs profiling in colorectal cancer liver metastases reveals novel molecular subtypes with prognostic and therapeutic relevance.结直肠癌肝转移中增强子RNA谱分析揭示了具有预后和治疗相关性的新型分子亚型。
Discov Oncol. 2025 Jun 11;16(1):1052. doi: 10.1007/s12672-025-02879-4.
2
Enhancer RNA in cancer: identification, expression, resources, relationship with immunity, drugs, and prognosis.癌症中的增强子RNA：鉴定、表达、资源、与免疫的关系、药物及预后
Brief Funct Genomics. 2025 Jan 15;24. doi: 10.1093/bfgp/elaf007.
3
Integrated Analysis of Bulk and Single-Cell RNA Sequencing Data Reveal a Novel Prognostic Signature of Combining Cuproptosis- and Ferroptosis-Related Genes in Hepatocellular Carcinoma.

本文引用的文献

1
Preoperative immune landscape predisposes adverse outcomes in hepatocellular carcinoma patients with liver transplantation.术前免疫格局使肝移植肝细胞癌患者易出现不良预后。
NPJ Precis Oncol. 2021 Mar 26;5(1):27. doi: 10.1038/s41698-021-00167-2.
2
An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma.头颈鳞状细胞癌的免疫相关基因预后指数。
Clin Cancer Res. 2021 Jan 1;27(1):330-341. doi: 10.1158/1078-0432.CCR-20-2166. Epub 2020 Oct 23.
3
Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype.
批量和单细胞RNA测序数据的综合分析揭示了一种新的肝细胞癌中铜死亡和铁死亡相关基因组合的预后特征。
Int J Mol Sci. 2025 Mar 19;26(6):2779. doi: 10.3390/ijms26062779.
4
CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression.CRISPR 筛选转录超级增强子鉴定三阴性乳腺癌进展的驱动因素。
Cancer Res. 2024 Nov 4;84(21):3684-3700. doi: 10.1158/0008-5472.CAN-23-3995.
5
Comprehensive profiling of enhancer RNA in stage II/III colorectal cancer defines two prognostic subtypes with implications for immunotherapy.全面分析 II/III 期结直肠癌中的增强子 RNA，定义了两种具有免疫治疗意义的预后亚型。
Clin Transl Oncol. 2024 Apr;26(4):891-904. doi: 10.1007/s12094-023-03319-x. Epub 2023 Sep 12.
6
Exploring the potential of eRNAs in cancer immunotherapy.探索eRNAs在癌症免疫治疗中的潜力。
Mol Ther Oncolytics. 2022 Nov 8;27:197-199. doi: 10.1016/j.omto.2022.10.009. eCollection 2022 Dec 15.
肺腺癌中功能性增强子RNA的综合表征揭示了新的调节因子和一种预后相关的分子亚型。
Theranostics. 2020 Sep 14;10(24):11264-11277. doi: 10.7150/thno.47039. eCollection 2020.
4
A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer.高分辨率人类增强子 RNA 图谱描绘癌症中超增强子的活性。
Cancer Cell. 2020 Nov 9;38(5):701-715.e5. doi: 10.1016/j.ccell.2020.08.020. Epub 2020 Oct 1.
5
Spirits in the Material World: Enhancer RNAs in Transcriptional Regulation.物质世界中的精灵：转录调控中的增强子 RNA。
Trends Biochem Sci. 2021 Feb;46(2):138-153. doi: 10.1016/j.tibs.2020.08.007. Epub 2020 Sep 1.
6
The genomic landscape of Mongolian hepatocellular carcinoma.蒙古肝细胞癌的基因组图谱。
Nat Commun. 2020 Sep 1;11(1):4383. doi: 10.1038/s41467-020-18186-1.
7
Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma.拷贝数改变负担对肝细胞癌的免疫谱和分子特征有差异影响。
Clin Cancer Res. 2020 Dec 1;26(23):6350-6361. doi: 10.1158/1078-0432.CCR-20-1497. Epub 2020 Sep 1.
8
The T cell differentiation landscape is shaped by tumour mutations in lung cancer.肺癌中的肿瘤突变塑造了 T 细胞分化的景观。
Nat Cancer. 2020 May;1(5):546-561. doi: 10.1038/s43018-020-0066-y. Epub 2020 May 22.
9
Multi-omics analysis reveals the functional transcription and potential translation of enhancers.多组学分析揭示了增强子的功能转录和潜在翻译。
Int J Cancer. 2020 Oct 15;147(8):2210-2224. doi: 10.1002/ijc.33132. Epub 2020 Jul 1.
10
TIMER2.0 for analysis of tumor-infiltrating immune cells.TIMER2.0 用于分析肿瘤浸润免疫细胞。
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514. doi: 10.1093/nar/gkaa407.